HR 2315 · 113th Congress · Health
Preserving Access to Orphan Drugs Act of 2013
Bill Progress
✓
Introduced2
Committee3
House Vote4
Senate5
EnactedLatest: Rereferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.(2013-07-25)
Plain Language Summary
[AI summary unavailable — showing source text]
Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million. Makes this Act effective as if included in PPACA.…
Summarized by Claude AI · Non-partisan · For informational purposes only
Cosponsors (20)
9 Democrats11 Republicans